How Long Are Allergy Shots? The 3-5 Year Investment vs 30 Years of Medications

For patients with confirmed IgE-mediated allergic rhinitis or asthma, clinical evidence and cost-effectiveness analyses consistently suggest SCIT is worth the investment on a long-term horizon. Hankin et al.'s Medicaid analysis in Annals of Allergy 2010 found 33 percent lower total healthcare costs in allergy shot patients versus matched controls, with savings emerging within 3 months. A quality-adjusted life-year analysis by Hankin et al. in JACI 2013 found SCIT superior to pharmacotherapy alone at a 10-year horizon. Additionally, the Moller et al. PAT study in JACI 2002 demonstrated that 3 years of SCIT in children cut asthma risk roughly in half — and asthma management costs approximately $3,266 per year per CDC data, meaning asthma prevention alone justifies the investment.

A 3-year insured allergy shot course costs approximately $4,500 to $6,500. Daily OTC allergy management — generic cetirizine ($15 to $30 per year) plus fluticasone nasal spray ($30 to $50 per year OTC) — runs approximately $150 to $400 per year. Over 30 years, that totals $4,500 to $12,000 for OTC options and $15,000 to $45,000 for prescription-based allergy management. These pharmacotherapy costs produce zero disease modification and no post-treatment benefit — you are paying each year for that year's symptom relief only. SCIT's front-loaded cost delivers benefits that extend 3 to 12 years after treatment ends, per Durham et al. in NEJM 1999 and Eng et al. in Allergy 2006.

The financial break-even point for allergy shots — where cumulative SCIT cost equals cumulative pharmacotherapy cost — is approximately 5 to 8 years after starting treatment, depending on insurance status, medication regimen, and whether productivity losses are counted. The break-even calculation assumes the SCIT patient substantially reduces or eliminates daily medications post-treatment (which 50 to 80 percent of patients achieve per Calderon et al.'s Cochrane review) while the pharmacotherapy patient continues spending $150 to $1,500 per year. After the break-even point, every additional year of post-treatment benefit represents net savings. For patients who prevent asthma development through SCIT, the savings are substantially larger due to asthma's $3,266 average annual management cost.

Medicare Part B covers allergy shots when administered by a qualified allergist, typically reimbursing at 80 percent after the deductible for allergen extract preparation (CPT 95165) and injection administration (CPT 95115 or 95117). Most Medicare beneficiaries pay 20 percent of the Medicare-approved amount after their Part B deductible. Medicaid coverage varies by state but generally covers allergy immunotherapy as a medically necessary treatment for IgE-mediated allergic conditions. Hankin et al.'s Florida Medicaid study in JACI 2008 confirmed that allergy shots were available to Medicaid-enrolled children, and the follow-up cost analysis demonstrated significant total healthcare cost savings in the treated population. Contact your specific plan for prior authorization requirements and covered codes.

Evidence from the PAT study and related research suggests SCIT in children with allergic rhinitis may significantly reduce asthma risk — a benefit with substantial long-term financial implications. The PAT study by Moller et al. in JACI 2002 found that 3 years of grass or birch SCIT reduced asthma development with an odds ratio of 2.52; Jacobsen et al.'s 10-year follow-up confirmed 25 percent of treated children developed asthma versus 45 percent of controls. Asthma carries an average annual management cost of approximately $3,266 per CDC 2019 data. Over a decade, preventing asthma saves more than $30,000. When asthma prevention is factored into SCIT's ROI, the treatment becomes substantially more cost-effective, with the break-even point moving earlier in the cost curve.

Productivity losses from weekly allergy shot appointments — particularly during the build-up phase — are a frequently overlooked component of in-clinic SCIT's total cost. Each clinic visit requires approximately 60 to 90 minutes including travel and the 30-minute post-injection observation. During conventional build-up at 1 to 2 visits per week, a patient may lose 2 to 3 hours of productive time per week for 6 months. Meltzer et al. in Annals of Allergy Asthma Immunology 2012 estimated that untreated allergies cause $600 to $1,200 per year in reduced work productivity. This schedule burden is real during build-up but ends completely after 3 to 5 years; untreated allergic disease continues eroding productivity indefinitely. The travel portion of that cost is also avoidable: with an at-home program such as Curex, eligible patients self-administer the same shots at home — the dosing time and short observation remain, but the commute disappears.